{"id":3532,"date":"2020-04-22T16:00:25","date_gmt":"2020-04-22T20:00:25","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/"},"modified":"2026-09-24T00:08:43","modified_gmt":"2026-09-24T04:08:43","slug":"gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/","title":{"rendered":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos"},"content":{"rendered":"\n<strong>Paris, France, le 22 avril 2020, 18h00 CEST <\/strong>\u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la tenue \u00e0 huis-clos de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 29 avril 2020 \u00e0 9h00 CEST.\n\nAfin de garantir la s\u00e9curit\u00e9 de tous, et dans le respect des consignes sanitaires promulgu\u00e9es par le gouvernement visant \u00e0 lutter contre la pand\u00e9mie de COVID-19, le Conseil d\u2019administration a d\u00e9cid\u00e9 de tenir l\u2019Assembl\u00e9e G\u00e9n\u00e9rale \u00e0 huis-clos, c\u2019est-\u00e0-dire hors la pr\u00e9sence des actionnaires et des autres personnes ayant le droit d\u2019y assister.\n\nGenSight Biologics invite donc ceux de ses actionnaires qui avaient pr\u00e9vu de se rendre \u00e0 son Assembl\u00e9e G\u00e9n\u00e9rale \u00e0 donner pouvoir au Pr\u00e9sident de l\u2019Assembl\u00e9e ou \u00e0 voter par correspondance via le formulaire pr\u00e9vu \u00e0 cet effet et t\u00e9l\u00e9chargeable sur le site de la Soci\u00e9t\u00e9 (<a href=\"https:\/\/www.gensight-biologics.com\">www.gensight-biologics.com<\/a>). Les modalit\u00e9s de vote figurent en d\u00e9tails dans l\u2018avis de convocation paru au BALO et dans un journal d\u2019annonces l\u00e9gales le 13 avril 2020.\n\nLa Soci\u00e9t\u00e9 indique \u00e9galement que, par d\u00e9rogation au III de l&rsquo;article R. 225-85 du code de commerce, un actionnaire qui aurait d\u00e9j\u00e0 exprim\u00e9 son vote \u00e0 distance, envoy\u00e9 un pouvoir ou demand\u00e9 sa carte d&rsquo;admission ou une attestation de participation, peut choisir un autre mode de participation \u00e0 l&rsquo;Assembl\u00e9e sous r\u00e9serve que son instruction en ce sens parvienne dans des d\u00e9lais compatibles avec les r\u00e8gles relatives \u00e0 chaque mode de participation. Les pr\u00e9c\u00e9dentes instructions re\u00e7ues sont alors r\u00e9voqu\u00e9es.\n\nL\u2019Assembl\u00e9e sera retransmise en direct le 29 avril \u00e0 9h00 CEST par <em>webcast<\/em> et conf\u00e9rence t\u00e9l\u00e9phonique en fran\u00e7ais sur le site de la Soci\u00e9t\u00e9 (<a href=\"https:\/\/www.gensight-biologics.com\">www.gensight-biologics.com<\/a>). Il sera possible de poser des questions par \u00e9crit \u00e0 l\u2019issue des pr\u00e9sentations et de l\u2019annonce des r\u00e9sultats du vote des r\u00e9solutions. Une rediffusion sera disponible \u00e0 l\u2019issue de l\u2019Assembl\u00e9e.\n\n&nbsp;\n<h3><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, LUMEVOQ<sup>\u00ae<\/sup> (GS010\u00a0; lenadogene nolparvovec), est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans l\u2019\u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 22 avril 2020, 18h00 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la tenue \u00e0 huis-clos de son Assembl\u00e9e [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76],"post-year":[],"class_list":["post-3532","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 22 avril 2020, 18h00 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la tenue \u00e0 huis-clos de son Assembl\u00e9e [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-22T20:00:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:08:43+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/04\\\/22\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/04\\\/22\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos\",\"datePublished\":\"2020-04-22T20:00:25+00:00\",\"dateModified\":\"2026-09-24T04:08:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/04\\\/22\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\\\/\"},\"wordCount\":574,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/04\\\/22\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/04\\\/22\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\\\/\",\"name\":\"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-04-22T20:00:25+00:00\",\"dateModified\":\"2026-09-24T04:08:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/04\\\/22\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/04\\\/22\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/04\\\/22\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos - GenSight Biologics","og_description":"Paris, France, le 22 avril 2020, 18h00 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la tenue \u00e0 huis-clos de son Assembl\u00e9e [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/","og_site_name":"GenSight Biologics","article_published_time":"2020-04-22T20:00:25+00:00","article_modified_time":"2026-09-24T04:08:43+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos","datePublished":"2020-04-22T20:00:25+00:00","dateModified":"2026-09-24T04:08:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/"},"wordCount":574,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/","name":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2020-04-22T20:00:25+00:00","dateModified":"2026-09-24T04:08:43+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/04\/22\/gensight-biologics-tiendra-son-assemblee-generale-mixte-du-29-avril-2020-a-huis-clos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 29 avril 2020 \u00e0 huis-clos"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3532"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3532\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3532"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3532"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3532"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3532"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}